LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Inicio・Lista de Acciones・Altimmune Inc

Altimmune Inc

Cerrado

3.4 -3.41

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.36

Máximo

3.52

Métricas clave
By Trading Economics
Ingresos	-8.3M -27M
Ventas	21K 26K
Margen de beneficios	-105,223.077
Empleados	57
EBITDA	-10M -29M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+290.93% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-68M 453M
Apertura anterior	6.81
Cierre anterior	3.4

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

5.365 / 6.0486 Soporte y Resistencia

Altimmune Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 mar 2026, 22:51 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18 mar 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18 mar 2026, 20:31 UTC

Ganancias

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18 mar 2026, 23:49 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18 mar 2026, 23:31 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery -- Market Talk

18 mar 2026, 22:49 UTC

Charlas de Mercado

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18 mar 2026, 22:41 UTC

Charlas de Mercado

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18 mar 2026, 22:36 UTC

Ganancias

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18 mar 2026, 22:24 UTC

Ganancias

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18 mar 2026, 22:23 UTC

Ganancias

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18 mar 2026, 21:58 UTC

Ganancias

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

18 mar 2026, 21:55 UTC

Charlas de Mercado

Ganancias

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18 mar 2026, 21:40 UTC

Charlas de Mercado

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18 mar 2026, 21:16 UTC

Charlas de Mercado

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18 mar 2026, 21:00 UTC

Noticias de Eventos Importantes

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18 mar 2026, 20:58 UTC

Ganancias

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18 mar 2026, 20:41 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:29 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:25 UTC

Ganancias

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18 mar 2026, 20:17 UTC

Ganancias

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18 mar 2026, 20:14 UTC

Charlas de Mercado

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18 mar 2026, 20:09 UTC

Ganancias

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18 mar 2026, 20:07 UTC

Ganancias

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18 mar 2026, 20:06 UTC

Ganancias

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18 mar 2026, 20:04 UTC

Ganancias

Micron Technology Sees 3Q Gross Margin About 81% >MU

18 mar 2026, 20:03 UTC

Ganancias

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Comparación entre iguales

Cambio de precio

Altimmune Inc previsión

Precio Objetivo

By TipRanks

290.93% repunte

Estimación a 12 Meses

Media 13.8 USD 290.93%

Máximo 25 USD

Mínimo 4.01 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Altimmune Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Altimmune Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

5.365 / 6.0486Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.